Logo image of YMAB

Y-MABS THERAPEUTICS INC (YMAB) Stock Fundamental Analysis

NASDAQ:YMAB - Nasdaq - US9842411095 - Common Stock - Currency: USD

4.8  -0.14 (-2.83%)

After market: 5.04 +0.24 (+5%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to YMAB. YMAB was compared to 557 industry peers in the Biotechnology industry. YMAB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, YMAB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

YMAB had negative earnings in the past year.
In the past year YMAB has reported a negative cash flow from operations.
In the past 5 years YMAB always reported negative net income.
YMAB had a negative operating cash flow in each of the past 5 years.
YMAB Yearly Net Income VS EBIT VS OCF VS FCFYMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -25.07%, YMAB is in the better half of the industry, outperforming 72.89% of the companies in the same industry.
Looking at the Return On Equity, with a value of -31.56%, YMAB is in the better half of the industry, outperforming 76.12% of the companies in the same industry.
Industry RankSector Rank
ROA -25.07%
ROE -31.56%
ROIC N/A
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
YMAB Yearly ROA, ROE, ROICYMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

YMAB has a better Gross Margin (82.06%) than 86.18% of its industry peers.
In the last couple of years the Gross Margin of YMAB has declined.
YMAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 82.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
YMAB Yearly Profit, Operating, Gross MarginsYMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

YMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
YMAB has more shares outstanding than it did 1 year ago.
YMAB has more shares outstanding than it did 5 years ago.
There is no outstanding debt for YMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
YMAB Yearly Shares OutstandingYMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
YMAB Yearly Total Debt VS Total AssetsYMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

YMAB has an Altman-Z score of 0.37. This is a bad value and indicates that YMAB is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.37, YMAB is doing good in the industry, outperforming 64.45% of the companies in the same industry.
YMAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.37
ROIC/WACCN/A
WACC9.1%
YMAB Yearly LT Debt VS Equity VS FCFYMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

A Current Ratio of 4.77 indicates that YMAB has no problem at all paying its short term obligations.
YMAB has a Current ratio (4.77) which is in line with its industry peers.
YMAB has a Quick Ratio of 4.35. This indicates that YMAB is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.35, YMAB perfoms like the industry average, outperforming 49.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.77
Quick Ratio 4.35
YMAB Yearly Current Assets VS Current LiabilitesYMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

YMAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.61%.
YMAB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.93%.
Measured over the past years, YMAB shows a very strong growth in Revenue. The Revenue has been growing by 35.95% on average per year.
EPS 1Y (TTM)-30.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)4.93%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%4.88%

3.2 Future

Based on estimates for the next years, YMAB will show a small growth in Earnings Per Share. The EPS will grow by 4.63% on average per year.
YMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.88% yearly.
EPS Next Y-58.02%
EPS Next 2Y-28.15%
EPS Next 3Y-14.82%
EPS Next 5Y4.63%
Revenue Next Year-7.06%
Revenue Next 2Y3.56%
Revenue Next 3Y6.58%
Revenue Next 5Y17.88%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
YMAB Yearly Revenue VS EstimatesYMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
YMAB Yearly EPS VS EstimatesYMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for YMAB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YMAB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YMAB Price Earnings VS Forward Price EarningsYMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YMAB Per share dataYMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as YMAB's earnings are expected to decrease with -14.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.15%
EPS Next 3Y-14.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for YMAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Y-MABS THERAPEUTICS INC

NASDAQ:YMAB (6/17/2025, 8:27:32 PM)

After market: 5.04 +0.24 (+5%)

4.8

-0.14 (-2.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11/amc
Inst Owners71.01%
Inst Owner Change13.61%
Ins Owners1.16%
Ins Owner Change5.34%
Market Cap217.34M
Analysts80
Price Target14.65 (205.21%)
Short Float %6.73%
Short Ratio12.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.77%
Min EPS beat(2)-18.84%
Max EPS beat(2)44.37%
EPS beat(4)2
Avg EPS beat(4)-7.68%
Min EPS beat(4)-56.65%
Max EPS beat(4)44.37%
EPS beat(8)5
Avg EPS beat(8)12.5%
EPS beat(12)8
Avg EPS beat(12)19.57%
EPS beat(16)10
Avg EPS beat(16)15.17%
Revenue beat(2)1
Avg Revenue beat(2)-0.14%
Min Revenue beat(2)-4.81%
Max Revenue beat(2)4.54%
Revenue beat(4)1
Avg Revenue beat(4)-6.34%
Min Revenue beat(4)-22.2%
Max Revenue beat(4)4.54%
Revenue beat(8)3
Avg Revenue beat(8)-3.68%
Revenue beat(12)6
Avg Revenue beat(12)4.05%
Revenue beat(16)7
Avg Revenue beat(16)3.58%
PT rev (1m)-9.2%
PT rev (3m)-27.27%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-67.13%
Revenue NQ rev (1m)-2.64%
Revenue NQ rev (3m)-11.39%
Revenue NY rev (1m)-0.19%
Revenue NY rev (3m)-20.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.45
P/FCF N/A
P/OCF N/A
P/B 2.43
P/tB 2.49
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-1.1
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS1.96
BVpS1.98
TBVpS1.93
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.07%
ROE -31.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 82.06%
FCFM N/A
ROA(3y)-36.35%
ROA(5y)-45.09%
ROE(3y)-46.99%
ROE(5y)-56.89%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.89%
GM growth 5YN/A
F-Score3
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.77
Quick Ratio 4.35
Altman-Z 0.37
F-Score3
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-58.02%
EPS Next 2Y-28.15%
EPS Next 3Y-14.82%
EPS Next 5Y4.63%
Revenue 1Y (TTM)4.93%
Revenue growth 3Y35.95%
Revenue growth 5YN/A
Sales Q2Q%4.88%
Revenue Next Year-7.06%
Revenue Next 2Y3.56%
Revenue Next 3Y6.58%
Revenue Next 5Y17.88%
EBIT growth 1Y-16.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-66.33%
EBIT Next 3Y-1.57%
EBIT Next 5YN/A
FCF growth 1Y69.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.13%
OCF growth 3YN/A
OCF growth 5YN/A